Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Clavis Pharma makes board appointments

This article was originally published in Scrip

Executive Summary

The Norwegian cancer drug development company Clavis Pharma has elected Anders Wiklund and Annette Clancy to serve on its board of directors as chairman and non-executive director, respectively. The appointments were made at Clavis's annual general meeting held in Oslo on 20 May, when former chairman Keith McCullagh, Gert Caspritz and Stina Gestrelius also stepped down from the board. Mr Wiklund has 40 years' business and corporate development experience in the biotechnology and pharmaceutical industries. He spent 29 years with the Kabi and Pharmacia group of companies, where he served in a number of positions, including managing director of KabiVitrum (UK), president of KabiVitrum International (Sweden), and president and CEO of KabiVitrum and KabiPharmacia (US). In 1997, he founded Wiklund International, an advisory firm to the biotech industry, and co-founded Esperion Therapeutics and served for several years on its board of directors before its acquisition by Pfizer for $1.3 billion. Ms Clancy has more than 25 years' experience in the pharmaceutical industry, predominantly with GlaxoSmithKline, where she worked in a variety of functions, including R&D, strategic marketing and licensing/business development. She currently serves as a senior advisor at the US-based venture capital firm Frazier Healthcare Ventures, as chair of GSK's respiratory R&D team and as a non-executive director at Silence Therapeutics.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts